SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-353219
Filing Date
2018-12-19
Accepted
2018-12-19 16:01:57
Documents
2
Period of Report
2018-12-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d674882d8k.htm 8-K 45284
2 EX-10.1 d674882dex101.htm EX-10.1 74898
  Complete submission text file 0001193125-18-353219.txt   121962
Mailing Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511
Business Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511 312 767 0291
MELINTA THERAPEUTICS, INC. /NEW/ (Filer) CIK: 0001461993 (see all company filings)

IRS No.: 454440364 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35405 | Film No.: 181243505
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences